Literature DB >> 8016795

Clonal analysis of lung and blood T cells in patients with sarcoidosis.

M J Garlepp1, A H Rose, J E Dench, B W Robinson.   

Abstract

BACKGROUND: Sarcoidosis is a disease characterised by clinical "anergy" to delayed type hypersensitivity antigens and the formation of non-caseating granulomas, which frequently manifests in the lungs as a T lymphocyte/mononuclear cell alveolitis. Although there is an increased proportion of T cells in bronchoalveolar lavage (BAL) samples from these patients, and these T cells often show evidence of activation and spontaneous secretion of cytokines such as interleukin 2 (IL-2) and interferon gamma (IFN gamma)--a pattern similar to delayed type hypersensitivity reactions--it is unclear whether both cytokines are produced by the majority of T cells derived from the lungs of patients with sarcoidosis or whether unique subpopulations of T cells produce each cytokine. In this study the properties of T cells cloned from BAL fluid samples of patients with sarcoidosis have been analysed.
METHODS: T cells were cloned by limiting dilution using IL-2, phytohaemagglutinin, and irradiated feeder cells. Cloning efficiencies were compared and phytohaemagglutinin induced clonal production of IL-2, IFN gamma, and IL-4 was determined by bioassay (IL-2 and IFN gamma) or ELISA (IL-4).
RESULTS: T cells derived from the BAL fluid of patients with sarcoidosis cloned less efficiently than those from blood of the same individuals. Lung derived clones (CD4+ or CD8+) produced IFN gamma more frequently and to a higher titre than blood derived clones, whereas IL-2 production by CD4+ clones derived from BAL fluid was less than that from blood derived clones. Interestingly, IL-4 production by clones from both sites was similar. Analysis of the co-production of IL-2, IFN gamma, and IL-4 by these BAL fluid clones did not demonstrate a predominant "Th1"-like population which has been suggested to underlie delayed type hypersensitivity reactions.
CONCLUSIONS: The reduced cloning efficiency of T cells from the lung compared with the blood in sarcoidosis is consistent with, although probably more pronounced than, previous observations in normal lungs and shows that T cell hyporesponsiveness is not overcome in the lungs of patients with sarcoidosis. Furthermore, major differences exist between the cytokine producing potential of T cells derived from the lung and the blood in sarcoidosis, and these parallel the differences in the properties of blood and lung T cells seen in healthy individuals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016795      PMCID: PMC474948          DOI: 10.1136/thx.49.6.577

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  26 in total

1.  Alveolar macrophages that suppress T-cell responses may be crucial to the pathogenetic outcome of pulmonary sarcoidosis.

Authors:  M A Spiteri; S W Clarke; L W Poulter
Journal:  Eur Respir J       Date:  1992-04       Impact factor: 16.671

Review 2.  Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts).

Authors:  R G Crystal; P B Bitterman; S I Rennard; A J Hance; B A Keogh
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

3.  A clonal analysis of lung T cells derived by bronchoalveolar lavage of healthy individuals.

Authors:  M J Garlepp; A H Rose; R V Bowman; N Mavaddat; J Dench; B J Holt; M Baron-Hay; P G Holt; B W Robinson
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

4.  Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patients.

Authors:  G Semenzato; C Agostini; L Trentin; R Zambello; M Chilosi; A Cipriani; E Ossi; M R Angi; L Morittu; G Pizzolo
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

5.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.

Authors:  D S Robinson; Q Hamid; S Ying; A Tsicopoulos; J Barkans; A M Bentley; C Corrigan; S R Durham; A B Kay
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

6.  Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis.

Authors:  P Pinkston; P B Bitterman; R G Crystal
Journal:  N Engl J Med       Date:  1983-04-07       Impact factor: 91.245

7.  Maintenance of granuloma formation in pulmonary sarcoidosis by T lymphocytes within the lung.

Authors:  G W Hunninghake; J E Gadek; R C Young; O Kawanami; V J Ferrans; R G Crystal
Journal:  N Engl J Med       Date:  1980-03-13       Impact factor: 91.245

8.  Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis.

Authors:  G W Hunninghake; G N Bedell; D C Zavala; M Monick; M Brady
Journal:  Am Rev Respir Dis       Date:  1983-10

9.  Ia-like antigens on T-cells and their subpopulations in pulmonary sarcoidosis and in hypersensitivity pneumonitis. Analysis of bronchoalveolar and blood lymphocytes.

Authors:  U Costabel; K J Bross; K H Rühle; G W Löhr; H Matthys
Journal:  Am Rev Respir Dis       Date:  1985-03

10.  Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity.

Authors:  G W Hunninghake; R G Crystal
Journal:  N Engl J Med       Date:  1981-08-20       Impact factor: 91.245

View more
  4 in total

1.  Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa.

Authors:  S Jain-Vora; A M LeVine; Z Chroneos; G F Ross; W M Hull; J A Whitsett
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

2.  T helper 1 cells and interferon gamma regulate allergic airway inflammation and mucus production.

Authors:  L Cohn; R J Homer; N Niu; K Bottomly
Journal:  J Exp Med       Date:  1999-11-01       Impact factor: 14.307

3.  Imbalance of pro- and anti-inflammatory cytokines in pulmonary sarcoidosis.

Authors:  J Müller-Quernheim
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

4.  Comparative analysis of circulating dendritic cell subsets in patients with atopic diseases and sarcoidosis.

Authors:  Yumeko Hayashi; Yoshiki Ishii; Mitsumi Hata-Suzuki; Ryo Arai; Kazuyuki Chibana; Akihiro Takemasa; Takeshi Fukuda
Journal:  Respir Res       Date:  2013-03-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.